Bank Of New York Mellon Corp Cerevel Therapeutics Holdings, Inc. Transaction History

Bank Of New York Mellon Corp

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2023 May 09, 2023	BUY	$22.82 - $35.32 $5.38 Million - $8.32 Million	235,698 New	235,698 $5.75 Billion
Q4 2022 Feb 14, 2023	BUY	$25.35 - $31.96 $5.95 Million - $7.5 Million	234,812 New	234,812 $7.41 Million
Q3 2022 Nov 14, 2022	BUY	$25.5 - $41.42 $455,506 - $739,885	17,863 Added 8.57%	226,405 $6.4 Million
Q2 2022 Aug 15, 2022	SELL	$20.62 - $37.15 $4.1 Million - $7.38 Million	-198,621 Reduced 48.78%	208,542 $5.51 Million
Q1 2022 May 11, 2022	SELL	$23.5 - $35.38 $779,495 - $1.17 Million	-33,170 Reduced 7.53%	407,163 $14.3 Million
Q4 2021 Feb 11, 2022	BUY	$29.21 - $44.64 $501,594 - $766,558	17,172 Added 4.06%	440,333 $14.3 Million
Q3 2021 Nov 12, 2021	BUY	$21.26 - $38.85 $864,644 - $1.58 Million	40,670 Added 10.63%	423,161 $12.5 Million
Q2 2021 Aug 11, 2021	SELL	$12.56 - $29.69 $5.63 Million - $13.3 Million	-448,297 Reduced 53.96%	382,491 $9.8 Million
Q1 2021 May 13, 2021	BUY	$12.37 - $17.74 $10 Million - $14.4 Million	809,151 Added 3739.66%	830,788 $11.4 Million
Q4 2020 Feb 09, 2021	BUY	$9.82 - $18.27 $212,475 - $395,307	21,637 New	21,637 $358,000

242

154M

2.19M

3.87M

Ticker CERE
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 155,752,000
Description
Cerevel Therapeutics Holdings, Inc., a clinical-stage biopharmaceutical company, engages in the development of various therapies for neuroscience diseases. It is developing emraclidine, a positive allosteric modulator (PAM) that is in phase 1b clinical trials for the treatment of schizophrenia; and Darigabat, a PAM, which is in Phase 2 proof-of-...

Get notified when there are updates to the investment portfolio of Bank Of New York Mellon Corp, based on Form 13F filings with the SEC.

Stay updated on Bank Of New York Mellon Corp with notifications on news.